Orphan drug? Another Breakthrough for“MS" - Global and China analysis. Are you ready?
- Global and China definition of orphan drugs
- Incidence and treatment progress of multiple sclerosis worldwide and in China
- Global sales of multiple sclerosis and comparison with sales in China
- Comparison of global and China treatment guidelines for multiple sclerosis
- Global and China new progress of multiple sclerosis
- Multiple sclerosis new asset recommendation
Event details
|
DATA Thursday September 19, 2019 VENUE Webex TIME 4:00 PM - 5:00 PM RSVP This is a FREE event VIP tckets priority for Lingmed current clients Please RSVP by September 18, 2019 |
PRESENTERS Lingling Cao, CEO & Founder Hank Wang, Medical advisor REGISTER +86 21 5386 3003 |
Agenda
| 16:00 - 16:10Linkedbio services & projects introductions by LingLing Cao |
| 16:10 - 16.45Orphan drug? Another Breakthrough for“MS" - Global and China analysis by Hank Wang |
| 16:45 - 16:55Panel discussions |
| 16:55 - 17:00Q&A |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |
 |
Hank Wang Medical advisor Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market |